Effects of an ashwagandha extract (KSM-66) on memory, attention, energy, and sleep in children: a randomised, double-blind, placebo-controlled, multi-national study

Clinical Research Australia0 个研究点目标入组 80 人开始时间: 2021年5月31日最近更新: 2022年4月4日

试验速览

暂无简介。

•1. Parent-reported concerns in child’s attention, concentration, or memory
•2. Child attends mainstream schooling and mainstream classing
•3. Child is a healthy male or female aged between 6 and 12 years
•4. Parent/legal guardian and child willing to provide a personally signed and dated informed consent indicating that they have been informed of all pertinent aspects of the trial.
•5. Child willing and able to take prescribed supplements
•6. Child’s BMI between 18 and 30 kg/m2
•7. There is no plan for the child to commence new treatments over the study period
•8. Parent and child fluent in English

•1. Current or 12-month history in a child of any psychiatric disorder (including ADHD)
•2. Child is currently taking pharmaceutical medications expected to affect behaviour and learning.
•3. Current or history of clinically significant chronic medical condition in the child including but not limited to cardiovascular disease, organic brain disorder, seizure, or diabetes.
•4. Any diagnosed learning disorder in the child
•5. Child is experiencing exceptional social/family stressors (e.g., serious illness in the family, recent parental separation, etc).
•6. Child is currently taking ashwagandha or other supplements that may affect cognition or sleep
•7. Child has had a significant surgery over the last year

发起方

Clinical Research Australia